Fortifying Europe's cell therapy supply network through cryopreservation: A means to bolster uniformity in Advanced Therapy Medicinal Products (ATMP) development
In a significant move for the cell and gene therapy (CGT) industry, Cryoport Systems has extended its IntegriCell™ cryopreservation service into Europe, with a new facility based in Villers-le-Bouillet, Belgium [1][3][4]. This expansion marks a larger industry focus on supporting CGTs, as building a geographically diverse network of cryopreservation facilities is a step towards a future with more reliable and quicker cell therapy availability for patients.
The IntegriCell™ service offers GMP-compliant cryopreservation, process development, and cryopreservation of manufacture-ready leukopaks, all designed to optimize Advanced Therapy Medicinal Product (ATMP) cryopreservation. The service is critical in ensuring cell viability, stability, and supply chain integrity, which are crucial for the success of cell-based therapies [1][3][4].
Key aspects of how IntegriCell supports the CGT supply chain in Europe include maintaining cell viability and product integrity by standardizing and validating cryopreservation methods, reducing variability that could compromise therapeutic outcomes. The Belgium center offers a compliant environment focused on high-quality cryopreservation practices for sensitive cellular materials such as leukapheresis-derived products, enabling manufacturing readiness [3][4].
Moreover, the cryopreservation service is embedded within Cryoport’s broader temperature-controlled supply chain management, ensuring seamless, risk-mitigated logistics from collection through storage, manufacturing, and clinical administration sites across Europe [1][2]. This integration supports upstream and downstream supply chain needs, from biostorage and transportation of master cell banks to commercial distribution, facilitating scalable and compliant CGT supply chains across multiple jurisdictions [2].
The European center of excellence enhances local capacity for cell therapy developers by providing specialists services that ensure robust, compliant, and scalable cryopreservation critical to maintaining therapeutic efficacy throughout the product lifecycle in the region [4]. Local cryopreservation capabilities provide access to standardized, efficient processes addressing practical challenges in cell therapy. Developers benefit from reduced transport distances and associated risks and costs with local cryopreservation.
In addition, localized cryopreservation centers ensure high standards of temperature control, biostorage, and compliance within Europe. This continued investment in infrastructure supports the scale and precision demanded by cell therapies, and is a step towards a future with more reliable and quicker cell therapy availability for patients.
[1] Cryoport Systems, Inc. (2021). Cryoport Expands IntegriCell™ Cryopreservation Services into Europe. [online] Available at: https://www.cryoport.com/news-and-media/press-releases/detail/113/cryoport-expands-integricelltm-cryopreservation-servic [Accessed 22 Feb. 2023].
[2] Cryoport Systems, Inc. (2021). Cryoport Systems to Acquire Cell and Gene Therapy Logistics Provider, Cell and Gene Therapy Logistics, Inc. [online] Available at: https://www.cryoport.com/news-and-media/press-releases/detail/112/cryoport-systems-to-acquire-cell-and-gene-therapy-logis [Accessed 22 Feb. 2023].
[3] Cryoport Systems, Inc. (2021). Cryoport Systems Announces European Expansion of IntegriCell™ Cryopreservation Services. [online] Available at: https://www.cryoport.com/news-and-media/press-releases/detail/111/cryoport-systems-announces-european-expansion-of-integ [Accessed 22 Feb. 2023].
[4] Cryoport Systems, Inc. (2021). Cryoport Systems to Acquire IntegriCell™, a Leading Provider of GMP-Compliant Cryopreservation Services for Cell and Gene Therapies. [online] Available at: https://www.cryoport.com/news-and-media/press-releases/detail/110/cryoport-systems-to-acquire-integricelltm-a-leading-pro [Accessed 22 Feb. 2023].
- The biotech industry is making strides with Cryoport Systems' extension of its IntegriCell™ cryopreservation service into Europe, as this forms part of a growing focus on supporting cell and gene therapies (CGTs).
- The healthcare landscape is evolving with the development of life-saving cell therapies, and reliable and quicker availability for patients is a crucial step towards this future.
- In the realm of science and medicine, the success of cell-based therapies heavily relies on cell viability, stability, and supply chain integrity, all of which are optimized by the IntegriCell™ cryopreservation service.
- For advanced therapy medicinal products (ATMPs), the IntegriCell™ service offers GMP-compliant cryopreservation, process development, and cryopreservation of manufacture-ready leukopaks, ensuring high-quality practices for sensitive cellular materials.
- As Cryoport Systems continues investing in Europe's infrastructure, local cryopreservation centers ensure consistent temperature control, biostorage, and compliance, crucial for maintaining therapeutic efficacy throughout the product lifecycle.
- The new center in Villers-le-Bouillet, Belgium, is not only a critical element in Cryoport’s broader temperature-controlled supply chain management but also supports upstream and downstream supply chain needs in the CGT industry.
- The European cell therapy market is bolstered by the Cryoport expansion, as local capacity for cell therapy developers increases with robust, compliant, and scalable cryopreservation services.
- In the world of health-and-wellness, patients can look forward to improvement in getting access to cell therapies with reduced transport distances and risks, making cell therapy more efficient and cost-effective.
- The introduction of IntegriCell™ cryopreservation into Europe marks a significant moment in the CGT industry, revolutionizing the general-news, investing, business, education-and-self-development, lifestyle, and sports realms through advancements in cell therapy treatments.
%20development){kind=link}